Perspective Therapeutics
CATX
135 hedge funds and large institutions have $151M invested in Perspective Therapeutics in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 49 increasing their positions, 31 reducing their positions, and 24 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 31
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
6% more funds holding
Funds holding: 127 → 135 (+8)
2.92% less ownership
Funds ownership: 72.82% → 69.91% (-2.9%)
37% less call options, than puts
Call options by funds: $331K | Put options by funds: $527K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
77% less capital invested
Capital invested by funds: $655M → $151M (-$504M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.9M |
| 2 |
Millennium Management
New York
|
+$10.6M |
| 3 |
PA
Perceptive Advisors
New York
|
+$9.72M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$7.21M |
| 5 |
Morgan Stanley
New York
|
+$7.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$44.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$39M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$12.3M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10M |
| 5 |
State Street
Boston,
Massachusetts
|
-$8.83M |
CATX Hedge Fund Activity: Q4 2024 in Review
135 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q4 2024, worth a combined $151M — down 77% from $655M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CATX positions and 24 closed out — a net gain of 12 holders — while 49 added to existing stakes and 31 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $36.9M. The largest seller was Commodore Capital, exiting entirely with an estimated $44.7M sold.
- 135 institutional investors held Perspective Therapeutics (CATX) as of Q4 2024, up from 127 in Q3 2024.
- Funds reported $151M of Perspective Therapeutics stock for Q4 2024, down 77% quarter-over-quarter.
- 36 funds opened new Perspective Therapeutics positions in Q4 2024 and 24 closed out, a net change of +12 holders.
- The largest Perspective Therapeutics buyer in Q4 2024 was Fidelity Investments, an estimated $36.9M added.
- The largest Perspective Therapeutics seller in Q4 2024 was Commodore Capital, an estimated $44.7M sold.
Based on aggregated 13F filings for Q4 2024.